Filing Details

Accession Number:
0000950170-24-072122
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-11 19:01:55
Reporting Period:
2024-06-11
Accepted Time:
2024-06-11 19:01:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222012 Noubar Afeyan C/O Flagship Pioneering, Inc.
55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-11 163,649 $148.29 7,937,145 No 4 S Indirect By Flagship Ventures Fund IV, L.P.
Common Stock Disposition 2024-06-11 31,531 $148.29 1,529,789 No 4 S Indirect By Flagship Ventures Fund IV-Rx, L.P.
Common Stock Disposition 2024-06-11 6,420 $149.40 7,930,725 No 4 S Indirect By Flagship Ventures Fund IV, L.P.
Common Stock Disposition 2024-06-11 1,232 $149.40 1,528,557 No 4 S Indirect By Flagship Ventures Fund IV-Rx, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Flagship Ventures Fund IV, L.P.
No 4 S Indirect By Flagship Ventures Fund IV-Rx, L.P.
No 4 S Indirect By Flagship Ventures Fund IV, L.P.
No 4 S Indirect By Flagship Ventures Fund IV-Rx, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,924 Indirect By Flagship Pioneering, Inc.
Common Stock 1,946,931 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  3. The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.